2022 Fiscal Year Final Research Report
Exploring the factors influencing NK cell sensitivity to lenalidomide in multiple myeloma
| Project/Area Number |
20K17368
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 54010:Hematology and medical oncology-related
|
|---|
| Research Institution | Akita University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | レナリドミド / KIR / NK細胞 / 多発性骨髄腫 |
|---|
| Outline of Final Research Achievements |
In a previous study, we showed an association between therapeutic efficacy of lenalidomide and dexamethasone combination therapy and NK cell activation in multiple myeloma. In this study, we explored the factors influencing NK cell sensitivity to lenalidomide in multiple myeloma. As a result, among the patients with the presence of KIR2DS2 or KIR2DS3, NK cells were activated after Ld therapy and the 2-year PFS was significantly better.
|
| Free Research Field |
造血器腫瘍
|
| Academic Significance and Societal Importance of the Research Achievements |
KIR2DS2またはKIR2DS3の活性型KIR遺伝子を持つ群ではレナリドミド治療後にNK細胞の活性化がみられ、良好な治療効果を示していた。骨髄腫細胞のHLAのLOHや患者ごとのHLA-KIRの組み合わせとレナリドミドの感受性の関連についても検討を重ねることで、多発性骨髄腫におけるNK細胞療法の意義の判断材料の一つとなり得る。
|
